350 related articles for article (PubMed ID: 33876216)
21. Cost-effectiveness analysis of the introduction of the human papillomavirus vaccine in Honduras.
Aguilar IB; Mendoza LO; García O; Díaz I; Figueroa J; Duarte RM; Perdomo G; Garcia AG; Janusz CB
Vaccine; 2015 May; 33 Suppl 1():A167-73. PubMed ID: 25919157
[TBL] [Abstract][Full Text] [Related]
22. The Participation of HPV-Vaccinated Women in a National Cervical Screening Program: Population-Based Cohort Study.
Herweijer E; Feldman AL; Ploner A; Arnheim-Dahlström L; Uhnoo I; Netterlid E; Dillner J; Sparén P; Sundström K
PLoS One; 2015; 10(7):e0134185. PubMed ID: 26218492
[TBL] [Abstract][Full Text] [Related]
23. Public health impact and cost effectiveness of routine and catch-up vaccination of girls and women with a nine-valent HPV vaccine in Japan: a model-based study.
Cody P; Tobe K; Abe M; Elbasha EH
BMC Infect Dis; 2021 Jan; 21(1):11. PubMed ID: 33407188
[TBL] [Abstract][Full Text] [Related]
24. Cervical cancer risk perceptions, sexual risk behaviors and sexually transmitted infections among Bivalent Human Papillomavirus vaccinated and non-vaccinated young women in Uganda - 5 year follow up study.
Kumakech E; Andersson S; Wabinga H; Musubika C; Kirimunda S; Berggren V
BMC Womens Health; 2017 Jun; 17(1):40. PubMed ID: 28576143
[TBL] [Abstract][Full Text] [Related]
25. Optimal human papillomavirus vaccination strategies to prevent cervical cancer in low-income and middle-income countries in the context of limited resources: a mathematical modelling analysis.
Drolet M; Laprise JF; Martin D; Jit M; Bénard É; Gingras G; Boily MC; Alary M; Baussano I; Hutubessy R; Brisson M
Lancet Infect Dis; 2021 Nov; 21(11):1598-1610. PubMed ID: 34245682
[TBL] [Abstract][Full Text] [Related]
26. Modelling the population-level impact of vaccination on the transmission of human papillomavirus type 16 in Australia.
Regan DG; Philp DJ; Hocking JS; Law MG
Sex Health; 2007 Sep; 4(3):147-63. PubMed ID: 17931528
[TBL] [Abstract][Full Text] [Related]
27. Occurrence of vaccine and non-vaccine human papillomavirus types in adolescent Finnish females 4 years post-vaccination.
Palmroth J; Merikukka M; Paavonen J; Apter D; Eriksson T; Natunen K; Dubin G; Lehtinen M
Int J Cancer; 2012 Dec; 131(12):2832-8. PubMed ID: 22492244
[TBL] [Abstract][Full Text] [Related]
28. Effectiveness of human papillomavirus vaccine against cervical precancer in Japan: Multivariate analyses adjusted for sexual activity.
Kudo R; Sekine M; Yamaguchi M; Hara M; Hanley SJB; Kurosawa M; Adachi S; Ueda Y; Miyagi E; Ikeda S; Yagi A; Enomoto T
Cancer Sci; 2022 Sep; 113(9):3211-3220. PubMed ID: 35730321
[TBL] [Abstract][Full Text] [Related]
29. Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study.
Tabrizi SN; Brotherton JM; Kaldor JM; Skinner SR; Liu B; Bateson D; McNamee K; Garefalakis M; Phillips S; Cummins E; Malloy M; Garland SM
Lancet Infect Dis; 2014 Oct; 14(10):958-66. PubMed ID: 25107680
[TBL] [Abstract][Full Text] [Related]
30. The estimated impact of natural immunity on the effectiveness of human papillomavirus vaccination.
Matthijsse SM; Hontelez JAC; Naber SK; van Rosmalen J; Rozemeijer K; Penning C; Bakker R; van Ballegooijen M; de Kok IMCM; de Vlas SJ
Vaccine; 2015 Oct; 33(41):5357-5364. PubMed ID: 26348405
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination.
Goldhaber-Fiebert JD; Stout NK; Salomon JA; Kuntz KM; Goldie SJ
J Natl Cancer Inst; 2008 Mar; 100(5):308-20. PubMed ID: 18314477
[TBL] [Abstract][Full Text] [Related]
32. Cervical cancer screening varies by HPV vaccination status among a National Cohort of privately insured young women in the United States 2006-2016.
Ba DM; McCall-Hosenfeld JS; Ssentongo P; Chinchilli VM; Agbese E; Liu G; Leslie DL; Du P
Medicine (Baltimore); 2021 Oct; 100(41):e27457. PubMed ID: 34731120
[TBL] [Abstract][Full Text] [Related]
33. HPV Vaccination and the Risk of Invasive Cervical Cancer.
Lei J; Ploner A; Elfström KM; Wang J; Roth A; Fang F; Sundström K; Dillner J; Sparén P
N Engl J Med; 2020 Oct; 383(14):1340-1348. PubMed ID: 32997908
[TBL] [Abstract][Full Text] [Related]
34. A Retrospective Cohort Study of Young Women Spontaneously Choosing to Be Vaccinated against HPV: Outcomes from Their First Cervical Cancer Screening Test.
Del Mistro A; Battagello J; Weis L; Bressan V; Selle V; Ramigni M; Dal Zotto A; Maggiolo A; Gori S; Frayle H; Zappa M; Zorzi M; The Consensus Study Veneto Working Group
Viruses; 2021 Mar; 13(3):. PubMed ID: 33809436
[TBL] [Abstract][Full Text] [Related]
35. Human papillomavirus prevalence among unvaccinated young female college students in Botswana: A cross-sectional study.
Ramatlho P; Grover S; Mathoma A; Tawe L; Matlhagela K; Ngoni K; Molebatsi K; Chilisa B; Zetola NM; Robertson ES; Paganotti GM; Ramogola-Masire D
S Afr Med J; 2022 Apr; 112(5):335-340. PubMed ID: 35587246
[TBL] [Abstract][Full Text] [Related]
36. Postpartum HPV Vaccination Rate and Differences in Background Characteristics Between HPV Vaccinated and Unvaccinated Postpartum Women: Strict Monitoring and Follow-Up of Postpartum HPV Vaccination Program.
Lee CY; Tseng CJ; Chang CC; Lee MC; Yang SF
Front Immunol; 2021; 12():626582. PubMed ID: 34054800
[TBL] [Abstract][Full Text] [Related]
37. Implementation of a human papillomavirus vaccination demonstration project in Malawi: successes and challenges.
Msyamboza KP; Mwagomba BM; Valle M; Chiumia H; Phiri T
BMC Public Health; 2017 Jun; 17(1):599. PubMed ID: 28651574
[TBL] [Abstract][Full Text] [Related]
38. Adapting cervical cancer screening for women vaccinated against human papillomavirus infections: The value of stratifying guidelines.
Pedersen K; Burger EA; Nygård M; Kristiansen IS; Kim JJ
Eur J Cancer; 2018 Mar; 91():68-75. PubMed ID: 29335156
[TBL] [Abstract][Full Text] [Related]
39. The Longitudinal Incidence of Human Papillomavirus Vaccination in Spanish Primary Care in the First 10 Years After Approval.
Martín-Merino E; Llorente-García A; Castillo Cano B; Montero Corominas D; Huerta-Álvarez C
Pharmaceut Med; 2019 Dec; 33(6):519-530. PubMed ID: 31933243
[TBL] [Abstract][Full Text] [Related]
40. Model-based impact and cost-effectiveness of cervical cancer prevention in the Extended Middle East and North Africa (EMENA).
Kim JJ; Sharma M; O'Shea M; Sweet S; Diaz M; Sancho-Garnier H; Seoud M
Vaccine; 2013 Dec; 31 Suppl 6():G65-77. PubMed ID: 24331822
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
